NeoGenomics (NASDAQ: NEO) reported Q2 EPS of $0.00, $0.01 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $24.4 million versus the consensus estimate of $25.43 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.